Artivion, Inc.AORT

NYSEHealthcareSurgical & Medical Instruments & Apparatus
Price (close)
$22.63
Market cap
$1.1B
P/E
—
Revenue (TTM)
$471.5M
Net income
-$3.2M
Dividend yield
—
1-year total return
-44.0%
Net margin
-0.7%
Revenue growth
16.4%
Debt / equity
0.82x

What Artivion, Inc. does.

Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X ® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Aortic arch stent grafts include our E-vita ® Open NEO, E-vita Open Plus, Arcevo™ LSA Hybrid Stent Graft System (“Arcevo LSA”), the Ascyrus Medical Dissection Stent (“AMDS”) hybrid prosthesis, the NEXUS ONE TM (“NEXUS ONE”), NEXUS DUO TM (“NEXUS DUO”), and NEXUS TRE TM (“NEXUS TRE”) aortic arch stent graft systems (the “NEXUS family of products”), and E-vita Thoracic 3G products. Abdominal stent grafts include our E-xtra Design Engineering, E-nside TM , Artivex TM , E-tegra TM , E-ventus TM BX, Tuva TM BX, and E-liac TM products. Surgical sealants include BioGlue ® Surgical Adhesive (“BioGlue”) products. In addition to these four major product families, we sell or distribute PhotoFix ® bovine surgical patches (“PhotoFix”) and CardioGenesis ® cardiac laser therapy (prior to our abandonment of the business as of June 30, 2023). We began to manufacture and supply PerClot ® hemostatic powder (“PerClot”) during the second quarter of 2023 (as part of the Transitional Manufacturing and Supply Agreement (“TMSA”) of the Baxter Transaction).

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$253.2M$298.8M$313.8M$354.0M$388.5M$441.3M
Net income-$16.7M-$14.8M-$19.2M-$30.7M-$13.4M$9.8M
Free cash flow$5.0M-$15.7M-$15.9M$9.1M$11.0M$839,000

More on AORT.

Figures from Artivion, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.